
The latest news and exclusive analysis across the FDA-regulated industries from former FDA professionals and industry experts. Save time gathering the critical industry intelligence you need to act on.
| Platform | Pricing | Freemium | Publishes | Daily | |
|---|---|---|---|---|---|
| Issues | 522 | Founded | 5 years ago | Last Issue | 4 days ago |
| Active | |||||

Watch now (50 mins) | The FDA loosens CMC requirements for cell and gene therapy products, publishes a yes/no flowchart that right-sizes human factors submissions, and we break down a new warning letter.
Welcome to Insider issue #50.
We went to Philly to give a talk and came home with a notebook full of everyone else's. Here are a few things we're still thinking about.
This is a guest post from Nick Capman, President and CEO of The FDA Group.
AICA, the Audit Intelligence Compliance Assistance, is a patent-pending AI-powered compliance auditing tool we launched this year that analyzes all of your QMS documentation at machine speed.
It eliminates the sampling and blind spots com...
The FDA is pulling postapproval reminders out of ANDA approval letters. We break down the new reference guidance that replaces them and the obligations every approved generic has to keep on its radar.
This guidance breakdown is available i...
The FDA says it's now run more than 100 inspections under the new rule. The top findings are not a huge surprise. Where they're surfacing is the real signal.
Today’s piece is for the device and medtech teams among us. As you know by now, t...
Subscribers, engagement, traffic and sponsorship for The FDA Group's Insider Newsletter.
| Subscribers | Engagement | 78 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
How this newsletter ranks in the official Substack charts.
| #92 |
The writers behind this newsletter.
The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates.
You can find recent issues that have been published by The FDA Group's Insider Newsletter on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
To see how many people subscribe to The FDA Group's Insider Newsletter, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
Newsletter advertising can be extremely effective when it's done right. Before you pitch The FDA Group's Insider Newsletter as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact The FDA Group's Insider Newsletter using the contact information provided and ask for a copy of their media kit.
Scroll up to where it says Related Newsletters to see other publications like The FDA Group's Insider Newsletter. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.